Three with­drawals in ad­vanced ovar­i­an can­cer spell trou­ble for PARP class

When As­traZeneca and Mer­ck’s PARP in­hibitor Lyn­parza was ap­proved for ad­vanced ovar­i­an can­cer back in 2014, FDA’s cur­rent On­col­o­gy Cen­ter of Ex­cel­lence di­rec­tor Richard Paz­dur tout­ed it as the first in a “tar­get­ed, more per­son­al­ized” new class of med­i­cines for pa­tients who of­ten re­lapse af­ter chemother­a­py.

Al­most a decade lat­er, that op­tion is once again off the ta­ble for some pa­tients as three phar­ma gi­ants yank late-stage in­di­ca­tions from their la­bels over a po­ten­tial in­creased risk of death.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.